Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: J Clin Lipidol. 2009;3(3):167–178. doi: 10.1016/j.jacl.2009.04.052

Figure 4.

Figure 4

End of study measurements in the combined atorvastatin/Slo-Niacin and Slo-Niacin/ atorvastatin groups. The reduction in LDL-C is the primary end point. The 12.48% reduction in TNF-alpha is not significant but the concentration change between baseline and the end of combination therapy was statistically significant at 0.041 (Table 2D).